Rapid Fire
Glucagon Manufacturing in PLI Scheme
- 01 Jul 2024
- 1 min read
- Recently, the government decided to manufacture a Glucagon-like peptide receptor agonist (GLP-1RA) drug in India under the Production Linked Incentive (PLI) scheme from 2026.
- GLP-1RA is a class of anti-diabetic drugs which are also used for weight loss.
- Apart from GLP-1RA, investors are planning to make other drugs like Ozempic (for diabetes), and Wegovy (for obesity) at the site and the PLI scheme will provide manufacturing avenues in India.
- The PLI scheme is an ambitious central scheme to scale up domestic manufacturing capability, accompanied by higher import substitution and employment generation.
- Launched in March 2020, the scheme at present covers 14 sectors.
- Under the scheme, Domestic and Foreign companies receive financial rewards for manufacturing in India, based on a percentage of their revenue over up to five years.
Read more: Production Linked Incentive Scheme
